ORR for BI-1808 combined with pembrolizumab represents a meaningful improvement over pembrolizumab monotherapy in recurrent ...
Two first-line trials involving pembrolizumab (Keytruda)-based combinations for the treatment of recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) delivered mixed results. While ...
Padcev is approved for use in combination with the programmed death 1 inhibitor Keytruda (pembrolizumab) or Keytruda QLEX (pembrolizumab and berahyaluronidase alfa-pmph) as neoadjuvant treatment and ...
Treatment with pembrolizumab plus enfortumab vedotin-ejfv resulted in a statistically significant improvement in EFS compared with radical cystectomy surgery alone. Topline results were announced from ...
In a preliminary analysis of the phase 2 EVOKE-02 trial, the investigational combination regimen showed an objective response rate of 56% in previously untreated patients with metastatic non–small ...
MSK radiation oncologist Dr. Nancy Lee helped design the clinical trial showing that immunotherapy given around surgery could reduce recurrence of some head and neck cancers. A phase 3 clinical trial ...
Microgravity experiments on the International Space Station helped Merck develop a faster subcutaneous version of Keytruda ...
1.1 Pembrolizumab is recommended as an option for treating tumours with high microsatellite instability (MSI) or mismatch repair (MMR) deficiency in adults with: 1.2 This recommendation is not ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback